Breast Cancer Therapeutics Market Analysis North America,Europe,Asia,Rest of World (ROW) - US,Canada,Germany,UK,China - Size and Forecast 2024-2028

Breast Cancer Therapeutics Market 2024-2028

The Breast Cancer Therapeutics Market size is forecast to increase by USD 15.64 billion at a CAGR of 8.4% between 2023 and 2028. Among the myriad challenges in healthcare, combating breast cancer mortality stands paramount. This malignancy manifests in the form of tumors that invade tissues, leading to potentially fatal consequences. While surgical tumor removal remains a cornerstone in treatment, advancements in oncology drugs/therapeutics offer promising avenues for combating this disease.

Additionally, hormonal therapies play a pivotal role in managing certain types of breast cancer. Detectable signs like red patches on the skin, abnormal growths in bones, and swollen lymph nodes necessitate immediate medical attention. However, the complexities of this disease can extend beyond the physical realm, often resulting in psychological distress and even breathing problems. Thus, a comprehensive approach, integrating medical, psychological, and supportive care, is imperative in addressing the multifaceted challenges posed by breast cancer.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Disease Type, Therapy, and Geography Analysis

Disease Type Analysis 

Invasive breast cancers

The invasive breast cancers segment is estimated to witness significant growth during the forecast period. The invasive ductal carcinoma segment also referred to as infiltrating ductal carcinoma, is characterized by the invasion of the fibrous or fatty tissue of the breast outside the lactiferous duct by cancerous cells. In addition, it is the most common type of breast cancer, accounting for about 80% of breast-cancer cases.

Get a glance at the market contribution of various segments Download PDF Sample

The invasive breast cancer segment was the largest segment and was valued at USD 22.55 billion in 2018. Moreover, symptoms of this form of cancer include swelling of the breast, skin irritation, breast pain, nipple pain, redness, nipple discharge, lumps in the underarm area, and dimpling around the nipple or on the breast skin. Besides mutations in the BRCA1, BRCA2, and ErbB2 genes, hormonal, environmental, and lifestyle factors such as smoking, poor nutrition, and prior radiation therapy administered to the chest area increase the risk of invasive breast cancer. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.

Therapy Analysis

Targeted therapy

Targeted therapy segment can be referred to as a type of cancer treatment that targets proteins and controls the growth, division, and spread of cancer cells; targeted therapeutics are either small-molecule drugs or monoclonal antibodies (MAbs). In addition, monoclonal antibodies, also known as therapeutic antibodies, are proteins produced in the lab. Moreover, the monoclonal antibodies mark cancer cells to destroy the target cancer cell found. Target therapy helps build the immune system to destroy cancer cells. In addition, it also helps cancer cells from grouping by interrupting signals that cause them to grow and divide without order. Furthermore, the major contributing factor to the growth of this market is the expected approvals of new therapeutics, which in turn drives the market during the forecast period.

Hormonal therapy

The growing adoption of targeted therapeutics that treat breast-cancer contributed to the slow pace of growth of this market, and it harmed the sales of hormonal therapeutics that treat breast-cancer. As a result, leading manufacturers such as Pfizer Inc., Novartis AG, and Bristol Myers Squibb Co. are entering into collaborations to increase the use of hormonal therapeutics. Moreover, manufacturers are focusing on developing combination therapeutics using hormonal and targeted therapeutics, some of which have entered the market. Hence, such factors are fuelling the market growth which in turn drives the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period.  Despite the high cost, the market in the North American region is showing significant growth due to the availability of reimbursement schemes in countries such as the US and Canada.  In addition, in the US, the Centers for Medicare and  Medicaid Services (CMS) provides reimbursements for the treatment and diagnosis of breast-cancer. For example, Trastuzumab and IBRANCE are covered under CMS reimbursement schemes. Furthermore, in the US, CMS introduced an array of value-based care models to control the costs of therapeutics. Hence, such factors are driving the market growth in North America during the forecast period.

Buy Full Report Now

Market Dynamics and Customer Landscape

The market is experiencing significant growth driven by the rising prevalence of breast cancer worldwide, prompting increased focus on therapeutic approaches and drugs to combat the disease. A notable trend in this market is the rise in strategic collaborations among pharmaceutical companies, research institutions, and healthcare organizations to accelerate the development of novel treatments and improve patient outcomes. However, a significant challenge facing the industry is the increasing approvals of biosimilars, which intensifies competition and underscores the need for innovation in treatment modalities.

Despite challenges, advancements in chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy offer promising avenues for personalized and effective breast cancer treatment. Moreover, initiatives such as breast cancer awareness campaigns and screening programs, coupled with the integration of artificial intelligence in diagnostics, contribute to early detection and better management of the disease, ultimately reducing breast cancer mortality rates. 

Key Market Drivers

One of the key factors driving the market growth is the rising prevalence of breast cancer. Cancer or malignant growth is known to occur in various anatomical sites in the body. In addition, globally, cancer affecting the breast is the most frequently diagnosed cancer in women. Furthermore, breast cancer was the second most common cancer and the fifth most common cause of mortality globally.

Moreover, although early diagnosis is used as a preventive approach, the risk of breast-cancer is unchanged. For example, as per the CDC, each year, about 237,000 cases and about 2,100 cases of breast-cancer are diagnosed in women and men, respectively, in the US. About 41,000 women and 450 men in the US die each year due to breast cancer. Hence, such factors are driving the market growth during the forecast period.

Significant Market Trends

A key factor shaping the market growth is the rise in strategic collaborations. Another major trend in the global market is the rising number of collaborations and acquisitions among manufacturers, research groups, and government bodies. In addition, to develop an ideal therapeutic approach to treat breast-cancer, leading manufacturers are acquiring therapeutics from other manufacturers through collaborations that are worth billions.

For instance, in August 2021, Gilead Sciences and Merck and Co. Inc. formed a clinical trial partnership and supply agreement to assess the efficacy of the formers Trodelvy along with the Keytruda to treat triple-negative breast cancer (TNBC). Therefore, the combination treatment will be analyzed as first-line therapy for locally advanced or metastatic TNBC patients. Hence, such strategic collaborations are positively impacting the market which, in turn, drives the market growth and trends during the forecast period.

Major Market Challenges

Increasing approvals of biosimilars is one of the key challenges hindering the market growth. Biosimilars or follow-on biologics can be referred to as laboratory-generated clones of expensive biologics and are known to cost 20%-25% less than their corresponding parent biologics. As a result, the emergence of biosimilars limits the growth of the market.

Moreover, regulatory approval of biosimilars is beneficial to patients, but it is not as beneficial for manufacturers. However, market players are developing biosimilars to ensure revenue generation from biologic therapeutics biosimilars nearing patent expiry dates, thereby restoring their financial position in the market. Hence, such factors are negatively impacting the market. Therefore, it is expected to hinder the market growth during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc: The company offers breast-cancer therapeutics such as Ibrutinib, which is an anti-neoplastic agent. It is formulated as hard gelatin capsules, tablets, film coated tablets, and suspension for oral route of administration.

Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, PerkinElmer Inc, Pfizer Inc., Puma Biotechnology Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Analyst Overview

The market continues to evolve with advancements in therapeutic approach & drugs, including hormone therapy and immunotherapy, offering new hope to patients worldwide. Despite ongoing breast cancer awareness and screening programs, mortality rates and morbidity remain significant concerns, especially in cases of metastatic hormone receptor-positive breast cancer.

Early detection through breast cancer screening programs enhances survival probabilities, enabling prompt intervention and combination with other treatments. Technologies like artificial intelligence aid in breast cancer diagnoses, identifying Breast cancer cells within Milk ducts and Milk-producing lobules.

Treatment modalities targeting specific receptors like epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) have shown promise, particularly in HER2-positive breast-cancer cases, including those with Brain metastasis. Medications such as Herceptin provide targeted therapy, improving outcomes for affected Females.

While hospital visits and recovery rates are crucial factors, lifestyle choices like managing obesity, reducing alcohol intake, and addressing hormone problems post menopause play a pivotal role. Family history and cancer type analysis guide personalized treatment strategies, supported by Government support and access to medications through hospital pharmacies and online pharmacies. Market forecasting drives ongoing research and development efforts, aiming to enhance patient outcomes and quality of life.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides market growth analysis of the latest market trends and analysis and growth opportunities from 2018 to 2028. 

• Disease Type Outlook
  • Invasive breast cancers
  • Ductal carcinoma in situ
• Therapy Outlook
  • Targeted therapy
  • Hormonal therapy
  • Chemotherapy
• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World (ROW)
    • Australia
    • Argentina
    • Brazil

Market Scope
Report Coverage	Details
Page number	168
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 8.4%
Market Growth 2024-2028	USD 15.64 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	7.49
Regional analysis	North America, Europe, Asia, and the Rest of the World (ROW)
Performing market contribution	North America at 46%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, PerkinElmer Inc, Pfizer Inc., Puma Biotechnology Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2023 and 2028
• Precise estimation of the size and its contribution to the market in focus on the parent market
• Detailed market growth and forecasting analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate market forecast about upcoming market growth trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
• Thorough market research and growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch